Sectors
APUS
Apimeds Pharmaceuticals US, Inc
0.68
1 x 0.65
1 x 0.68
bid
ask
+
0.04
6.04%
01:40 PM
timesize
| Ytd | -58.81% | |
| 1y | -66.06% |
0.62
day range
0.68
0.61
52 week range
40.31
| Open | 0.62 | Prev Close | 0.64 | Low | 0.62 | High | 0.68 | Mkt Cap | 801.09K |
| Vol | 16.23K | Avg Vol | 189.06K | EPS | -2.71 | P/E | -0.24 | Forward P/E | N/A |
| Beta | -0.32 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.12 | 200-d Avg | 11.86 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 12.19M | ||
| Research and Development Expense | 901.14K | ||
| Selling, General and Administrative Expense | 11.28M | ||
| Operating Income | -12.19M | ||
| Interest Expense | 859.41K | ||
| Net Income | -35.06M | ||
| Net Income Common Stock | -35.06M | ||
| Net Income Common Stock (USD) | -35.06M | ||
| Consolidated Income | -35.06M | ||
| Earnings per Basic Share | -2.26 | ||
| Earnings per Basic Share (USD) | -2.26 | ||
| Earnings per Diluted Share | -2.26 | ||
| Earning Before Interest & Taxes (EBIT) | -34.20M | ||
| Earning Before Interest & Taxes (USD) | -34.20M | ||
| Weighted Average Shares | 15.51M | ||
| Weighted Average Shares Diluted | 15.51M | ||
| Balance Sheet | |||
| Cash and Equivalents | 8.98M | ||
| Cash and Equivalents (USD) | 8.98M | ||
| Investments | 129.32M | ||
| Investments Current | 1.50M | ||
| Investments Non-Current | 127.82M | ||
| Current Assets | 13.15M | ||
| Property, Plant & Equipment Net | 228.37K | ||
| Total Assets | 141.22M | ||
| Debt Current | 9.43M | ||
| Total Debt | 9.55M | ||
| Current Liabilities | 14.58M | ||
| Debt Non-Current | 118.82K | ||
| Total Liabilities | 14.70M | ||
| Accumulated Retained Earnings (Deficit) | -45.45M | ||
| Shareholders Equity | 126.52M | ||
| Shareholders Equity (USD) | 126.52M | ||
| Assets Non-Current | 128.07M | ||
| Total Debt (USD) | 9.55M | ||
| Liabilities Non-Current | 118.82K | ||
| Trade and Non-Trade Payables | 2.98M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 20.04K | ||
| Net Cash Flow from Financing | 920.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -657.12K | ||
| Capital Expenditure | -9.39K | ||
| Issuance (Repayment) of Debt Securities | 995.00K | ||
| Net Cash Flow from Investing | 490.61K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 500.00K | ||
| Net Cash Flow from Operations | -2.07M | ||
| Share Based Compensation | 114.17K | ||